Vinay Prasad is returning to his role at the U.S. Food and Drug Administration to resume overseeing vaccine, gene therapy and ...

Vinay Prasad is returning to his role at the U.S. Food and Drug Administration, a little more than a week after he had left ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

WASHINGTON — Vinay Prasad is returning to the Food and Drug Administration to resume his role overseeing vaccine, gene ...

The FDA approved labeling changes for elivaldogene autotemcel (eli-cel; Skysona), a one-time gene therapy for patients with early, active cerebral adrenoleukodystrophy (CALD), to reflect new safety ...

After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...

Vinay Prasad, who was recently ousted as the top vaccine and gene therapy regulator at the US Food and Drug Administration, is returning to his role, the Department of Health and Human Services said ...

The human genome is made up of 23 pairs of chromosomes, the biological blueprints that make humans … well, human. But it ...

Net loss (GAAP) widened to $2.6 million, driven by increased expenses from the GPCR Therapeutics USA Inc. acquisition. Management issued a going concern warning, citing $7.9 million in cash and cash ...

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services (HHS).

Christmas has come a few days early for Spark Therapeutics after the FDA approved its ground-breaking gene therapy for a rare eye disease. It looked likely that the FDA would approve the US ...

Patients in the EU with Fanconi anaemia (FA) could soon have the first gene therapy option for the rare disease, as the EMA starts a review of Rocket Pharma’s RP-L102.